These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
501 related articles for article (PubMed ID: 17494640)
1. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice. Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640 [TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model. Hu H; Huang X; Tao L; Huang Y; Cui BA; Wang H Vaccine; 2009 Mar; 27(11):1758-63. PubMed ID: 19186202 [TBL] [Abstract][Full Text] [Related]
3. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Woo PC; Lau SK; Tsoi HW; Chen ZW; Wong BH; Zhang L; Chan JK; Wong LP; He W; Ma C; Chan KH; Ho DD; Yuen KY Vaccine; 2005 Oct; 23(42):4959-68. PubMed ID: 15993989 [TBL] [Abstract][Full Text] [Related]
4. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses. Huang J; Cao Y; Du J; Bu X; Ma R; Wu C Vaccine; 2007 Sep; 25(39-40):6981-91. PubMed ID: 17709158 [TBL] [Abstract][Full Text] [Related]
5. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. Faber M; Lamirande EW; Roberts A; Rice AB; Koprowski H; Dietzschold B; Schnell MJ J Gen Virol; 2005 May; 86(Pt 5):1435-1440. PubMed ID: 15831955 [TBL] [Abstract][Full Text] [Related]
6. Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice. Hu H; Tao L; Wang Y; Chen L; Yang J; Wang H Biotechnol Lett; 2009 Nov; 31(11):1685-93. PubMed ID: 19579009 [TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986 [TBL] [Abstract][Full Text] [Related]
8. Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS. Callendret B; Lorin V; Charneau P; Marianneau P; Contamin H; Betton JM; van der Werf S; Escriou N Virology; 2007 Jul; 363(2):288-302. PubMed ID: 17331558 [TBL] [Abstract][Full Text] [Related]
9. A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro. Wang X; Xu W; Tong D; Ni J; Gao H; Wang Y; Chu Y; Li P; Yang X; Xiong S Immunol Lett; 2008 Aug; 119(1-2):71-7. PubMed ID: 18533276 [TBL] [Abstract][Full Text] [Related]
10. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835 [TBL] [Abstract][Full Text] [Related]
11. Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice. Lu B; Tao L; Wang T; Zheng Z; Li B; Chen Z; Huang Y; Hu Q; Wang H Clin Vaccine Immunol; 2009 Jan; 16(1):73-7. PubMed ID: 18987164 [TBL] [Abstract][Full Text] [Related]
12. Construction of a eukaryotic expression plasmid encoding partial S gene fragments of the SARS-CoV and its potential utility as a DNA vaccine. He H; Tang Y; Qin X; Xu W; Wang Y; Liu X; Liu X; Xiong S; Li J; Zhang M; Duan M DNA Cell Biol; 2005 Aug; 24(8):516-20. PubMed ID: 16101350 [TBL] [Abstract][Full Text] [Related]
13. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Martin JE; Louder MK; Holman LA; Gordon IJ; Enama ME; Larkin BD; Andrews CA; Vogel L; Koup RA; Roederer M; Bailer RT; Gomez PL; Nason M; Mascola JR; Nabel GJ; Graham BS; Vaccine; 2008 Nov; 26(50):6338-43. PubMed ID: 18824060 [TBL] [Abstract][Full Text] [Related]
14. CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein. Zhao K; Yang B; Xu Y; Wu C Vaccine; 2010 Sep; 28(41):6666-74. PubMed ID: 20709007 [TBL] [Abstract][Full Text] [Related]
15. Immunization of mice with a DNA vaccine based on severe acute respiratory syndrome coronavirus spike protein fragment 1. Zhao B; Jin NY; Wang RL; Zhang LS; Zhang YJ Viral Immunol; 2006; 19(3):518-24. PubMed ID: 16987069 [TBL] [Abstract][Full Text] [Related]
16. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV. Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752 [TBL] [Abstract][Full Text] [Related]
17. Characterization of cytotoxic T-lymphocyte epitopes and immune responses to SARS coronavirus spike DNA vaccine expressing the RGD-integrin-binding motif. Poh WP; Narasaraju T; Pereira NA; Zhong F; Phoon MC; Macary PA; Wong SH; Lu J; Koh DR; Chow VT J Med Virol; 2009 Jul; 81(7):1131-9. PubMed ID: 19475608 [TBL] [Abstract][Full Text] [Related]
18. Optimization of a DNA vaccine against SARS. Zakhartchouk AN; Viswanathan S; Moshynskyy I; Petric M; Babiuk LA DNA Cell Biol; 2007 Oct; 26(10):721-6. PubMed ID: 17665998 [TBL] [Abstract][Full Text] [Related]
19. Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Sekimukai H; Iwata-Yoshikawa N; Fukushi S; Tani H; Kataoka M; Suzuki T; Hasegawa H; Niikura K; Arai K; Nagata N Microbiol Immunol; 2020 Jan; 64(1):33-51. PubMed ID: 31692019 [TBL] [Abstract][Full Text] [Related]
20. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]